Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
AB, Abbreviated, affinity, alleged, alleging, analytical, anatomical, ancillary, ANDA, answered, antiandrogen, antitrust, approach, arrive, artificial, attack, AUC, automated, Aytu, begun, biochemical, Biology, Bioscience, Biovitrum, breakthrough, Bribery, BSI, burden, cabazitaxel, CFO, CI, complement, compression, correctly, create, creating, delisted, Deutschland, device, discovered, distant, efficient, ehf, elevated, Emission, encouraging, evidenced, EXINI, expedited, expressly, Fabbio, family, FCPA, fewer, filgrastim, fluctuation, fluorinated, forecast, formula, futility, genericization, German, Gleason, GmbH, goal, Greece, headquartered, Heidelberg, Hirt, hospice, Iceland, illustrated, indirect, infusion, injunctive, instability, intent, intercompany, investee, jurisdiction, jury, Kabi, Kettering, leader, lesion, lessor, load, located, Lonza, Lund, machine, masking, Merck, methodology, moderate, modified, moiety, monetary, Myelosuppression, Mylan, nearest, noncontrolling, noncurrent, North, Norway, notification, obscured, older, ONALTATM, opposition, outlook, owner, Paragraph, Patrick, pattern, perception, PET, pharmacodynamic, pharmacy, Philidor, physical, physiologic, political, polymer, portal, Positron, precisely, predecessor, predictor, predominant, presence, produce, produced, prompt, provisional, prudent, PTC, publ, purview, PyL, quantification, quantify, quantity, radiographic, radiologic, recreate, recurrent, relocate, remittitur, renew, replicate, reproduce, residual, rest, restitution, Restoration, rolling, routinely, Russia, Rx, safer, saline, sample, scan, scheme, School, scintigraphy, score, serum, Sheldon, showed, showing, Similarly, skeletal, skeleton, slight, slightly, Sloan, Sobi, sophisticated, stable, staffing, stay, stayed, subpopulation, subtype, suit, suitable, Sweden, Swedish, symptomatic, systematic, team, tender, tool, Topography, TOWER, tracer, transient, translated, translation, Translational, treble, truth, UK, unanimously, undergone, unspecified, upheld, uptake, urology, user, UWO, verdict, version, viral, visceral, visibility, visualize, vitro, vivo, voting, wide, WTC, xerostomia
Removed:
Adolor, aggregated, angelo, collateralized, decide, diversified, exercisability, founder, Heath, impossible, individual, Israel, joint, jr, loan, lovallo, MedImmune, metabolization, MIP, multicentered, prostectomy, protein, radiotherapy, reclassified, recover, reimbursable, remained, requested, Robert, satisfaction, Science, student, subsidized, summarize, suspended, train, Treasurer
Filing tables
Filing exhibits
- 10-K Annual report
- 12.1 Exhibit 12.1 Ratio
- 21.1 Exhibit 21.1 Subsidiaries of Progenics Pharmaceuticals, Inc.
- 23.1 Exhibit 23.1 Consent of Ernst & Young LLP
- 31.1 Exhibit 31.1 Certification
- 31.2 Exhibit 31.2 Certification
- 32.1 Exhibit 32.1 Certification
- 32.2 Exhibit 32.2 Certification
- 10.47 Exhibit 10.47
- 10.48 Exhibit 10.48
- 10.49 Exhibit 10.49
- Download Excel data file
- View Excel data file
Related press release
PGNX similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-3 No. 333-193521) of Progenics Pharmaceuticals, Inc., |
(2) | Registration Statements (Form S-8 Nos. 333-197071, 333-183511, 333-176204, 333-160389, 333-143670 and 333-124910) pertaining to the 2005 Stock Incentive Plan of Progenics Pharmaceuticals, Inc., and |
(3) | Registration Statements (Form S-8 Nos. 333-120508 and 333-52277) pertaining to its Amended and Restated 1996 Stock Incentive Plan of Progenics Pharmaceuticals, Inc.; |
of our reports dated March 11, 2016, with respect to the consolidated financial statements and schedules of Progenics Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Progenics Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Progenics Pharmaceuticals, Inc. for the year ended December 31, 2015.
/s/ Ernst & Young LLP
Hartford, Connecticut
March 11, 2016